Molecular, Translational and Clinical Research on the Two Most Common Forms of Neurodegenerative Dementia: Alzheimer’s Disease and Dementia with Lewy Bodies

Napoli, Eleonora

doi:10.3390/ijms24097996

IJMS

2023

DOI: 10.3390/ijms24097996

|View full text |Cite

Molecular, Translational and Clinical Research on the Two Most Common Forms of Neurodegenerative Dementia: Alzheimer’s Disease and Dementia with Lewy Bodies

Eleonora Napoli

Abstract: While not a specific disease, dementia is a term used to describe the deterioration of cognitive function beyond what would be expected because of natural biological aging [...]

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Other1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A new era in Alzheimer’s disease management: exploring aducanumab’s potential

Jiang

2024

Third International Conference on Biological Engineering and Medical Science (ICBioMed2023)

View full text Add to dashboard Cite

Alzheimer's disease (AD) is a deadly neurological condition associated with symptoms of memory loss and progressive cognitive deterioration. As an age-related disorder, it has been challenging the medical departments globally, leading to profound social and economic implications. Although its pathogenesis is not fully understood, many scientists have reached a consensus on the relationship between amyloid-beta protein peptide accumulation and cognitive decline. Aducanumab, an innovative monoclonal antibody treatment, targets the aggregated plaques and seeks to promote clearance to delay disease progression. Unlike conventional medications, aducanumab is the first therapy that allows for direct binding with amyloidogenic agents and, theoretically, leads to the activation of the immune system. In this review, the author provides an overview of Aducanumab's mechanism and potential disadvantages, highlighting its critical role in slowing disease progression and emphasizing the controversy surrounding the accelerated approval. This paper also introduces investigational therapies that offer promising avenues offering hope for improved AD treatments and better quality of life for those affected. By revealing Aducanumab's journey from research laboratories to the clinic, the global medical community can better understand the pathophysiology of AD, which further pave the way for a more comprehensive approach to managing this devastating neurological condition in the future.

show abstract

A new era in Alzheimer’s disease management: exploring aducanumab’s potential

Jiang

2024

Third International Conference on Biological Engineering and Medical Science (ICBioMed2023)

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Molecular, Translational and Clinical Research on the Two Most Common Forms of Neurodegenerative Dementia: Alzheimer’s Disease and Dementia with Lewy Bodies

Abstract: While not a specific disease, dementia is a term used to describe the deterioration of cognitive function beyond what would be expected because of natural biological aging [...]

Cited by 1 publication

References 40 publications

A new era in Alzheimer’s disease management: exploring aducanumab’s potential

A new era in Alzheimer’s disease management: exploring aducanumab’s potential

Contact Info

Product

Resources

About